A Game-Changing Presentation at DDW 2025

Exciting news is coming out of the Digestive Disease Week® (DDW 2025) Annual Meeting, running from May 3-6 in sunny San Diego. Castle Biosciences, Inc. has unveiled groundbreaking data on its innovative TissueCypher Barrett’s Esophagus test, a tool designed to help identify patients at heightened risk for developing esophageal cancer. As experts unite to share knowledge in a series of enlightening sessions, the stakes for better patient outcomes have never been higher.

Forget the Waiting Game: A Personalized Approach to Barrett's Esophagus

Dr. Emmanuel Gorospe, a leading gastroenterologist and GI medical director at Castle Biosciences, emphasized the importance of the TissueCypher test, stating, "This compelling new data underlines how TissueCypher is critical in pinpointing high-risk Barrett's esophagus (BE) patients. We’re moving beyond the outdated 'wait and see' strategy to empower clinicians with personalized surveillance and proactive interventions that could potentially stop cancer before it starts."

Key Presentations to Watch

At DDW 2025, two pivotal posters will be highlighted, focusing on the advancements brought by the TissueCypher test: 1. **Poster Su1466:** Highlights the detection of missed neoplasia in patients with non-dysplastic Barrett’s esophagus, presented by Dr. Philip Woodworth. 2. **Poster Su1324:** Discusses the risk stratification offered by the TissueCypher test for Barrett’s esophagus patients, presented by Dr. Charles Randall.

These posters will premiere on Sunday, May 4, during the poster session from 12:30 to 1:30 p.m. PT, along with opportunities to engage directly with the presenters.

Product Theater: Time to Act!

On the same day, a product theater session titled, "The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC," will feature a panel of celebrated experts, including Dr. Vivek Kaul from the University of Rochester and Dr. Harshit Khara from Geisinger Medical Center. This vital discussion will take place from 2:45 to 3:30 p.m. PT, underscoring the urgency of proactive measures in managing Barrett’s esophagus.

Understanding the TissueCypher Barrett’s Esophagus Test

Designed as a precision medicine test, the TissueCypher Barrett’s Esophagus test predicts the future risk of high-grade dysplasia and esophageal cancer in patients with Barrett’s esophagus—transforming how we approach patient care. Its clinical efficacy is backed by numerous peer-reviewed studies, solidifying its status in the medical community.

A Future Focused on Innovation

Castle Biosciences continues to lead the charge in innovative diagnostics, also developing tests for various conditions, including skin cancers and mental health concerns. With a commitment to enhancing patient care, the company aims to transform disease management through their advanced testing solutions.

In a world where prevention is key, the data presented at DDW 2025 offers promising avenues for early intervention and improved outcomes for patients with Barrett’s esophagus. Stay tuned for more updates as these sessions unfold!